Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

NCT04383210 is registered in ClinicalTrials.gov with Elevation Oncology as lead sponsor.

NCT NCT04383210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04383210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Elevation Oncology
Phase
Phase 2
Overall status
Terminated
Start date
September 29, 2020
Completion date
February 28, 2024
Enrollment
54 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, bladder cancer, breast cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer, gallbladder cancer, head and neck cancer, kidney cancer, locally advanced solid tumor, lung cancer, metastatic solid tumor, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, uterine cancer